A study to assess the pharmacokinetics of AZD6793 when administered alone and in combination with itraconazole in healthy participants.

Study identifier:D7860C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2023-509002-30-00

Will Be Recruiting

Official Title

An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination with Itraconazole Capsules in Healthy Adult Female and Male Participants.

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6793+ Itraconazole, AZD6793, Itraconazole

Sex

All

Estimated Enrollment

16

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 23 Jul 2024
Estimated Primary Completion Date: 20 Sept 2024
Estimated Study Completion Date: 20 Sept 2024

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria